Form 4: MannKind EVP Granted Significant Equity Awards

Sanjay R Singh, MannKind's EVP of Technical Operations, received 221,000 performance-based restricted stock units and 217,000 employee stock options.

Summary

• Sanjay R Singh, EVP Technical Operations at MannKind Corp (MNKD), acquired derivative securities on March 23, 2026.
• The acquisition includes 221,000 Performance Restricted Stock Units (RSUs).
• These RSUs will vest on January 15, 2029, with the number of shares delivered determined by MannKind's Total Shareholder Return (TSR) relative to the Russell 3000 Pharmaceutical & Biotechnology Index.
• The TSR measurement period for the RSUs is from April 1, 2026, to December 31, 2028.
• Payout for RSUs ranges from 0% (less than 25th percentile TSR) to 300% (90th percentile or higher TSR) of the target, with interpolation for intermediate percentiles.
• The acquisition also includes 217,000 Employee Stock Options with an exercise price of $2.44.
• The stock options will vest 25% on March 23, 2027, and thereafter 1/16th quarterly.
• The employee stock options have an expiration date of March 23, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as it strengthens the alignment between executive incentives and shareholder value through performance-based equity awards.

Positives

• The grant of performance-based restricted stock units directly aligns executive compensation with shareholder returns, incentivizing long-term value creation for MannKind.
• Employee stock options provide a further incentive for the executive to contribute to the company's stock price appreciation, benefiting shareholders.

Negatives

• No direct negatives are apparent from this specific Form 4 filing, which reports an equity grant as part of executive compensation.

Risks

• The value of the performance-based restricted stock units is contingent on MannKind's Total Shareholder Return (TSR) performance relative to an industry index, introducing performance risk for the executive's ultimate payout.
• The value of the employee stock options is subject to the future market price of MannKind common stock, meaning they could be worthless if the stock price does not exceed the exercise price by the expiration date.

Future Outlook

The equity awards, particularly the performance-based RSUs, tie a significant portion of executive compensation to MannKind's future Total Shareholder Return (TSR) performance relative to its industry peers, indicating a strategic focus on long-term shareholder value creation.

Industry Context

StockSavvy.ai notes that performance-based equity awards, linked to relative TSR, are a common and increasingly preferred method of executive compensation in the pharmaceutical and biotechnology sectors. This structure aims to align executive incentives with shareholder interests and industry-specific performance benchmarks.

Comparison to Industry Standards

• The use of performance-based restricted stock units tied to relative Total Shareholder Return (TSR) against an industry index like the Russell 3000 Pharmaceutical & Biotechnology Index is a standard practice for executive compensation in the biotech and pharmaceutical industries.
• Companies such as Amgen, Gilead Sciences, and Biogen frequently utilize similar structures to incentivize long-term performance and align executive interests with shareholder value creation.
• The vesting schedule for stock options (25% after one year, then quarterly) is also a common approach to encourage executive retention and sustained performance.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with long-term shareholder value creation.
• Employees: No direct impact on general employees mentioned, but reflects the company's executive compensation strategy.

Next Steps

• MannKind's Total Shareholder Return (TSR) will be measured from April 1, 2026, to December 31, 2028, against the Russell 3000 Pharmaceutical & Biotechnology Index.
• The performance-based restricted stock units will vest on January 15, 2029, with the number of shares delivered determined by the relative TSR performance.
• Employee stock options will begin vesting on March 23, 2027, with subsequent quarterly vesting.

Key Dates

Keywords

MannKind, MNKD, Sanjay R Singh, EVP Technical Operations, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Insider Transaction, Equity Grant, Performance-based compensation, TSR, Russell 3000 Pharmaceutical & Biotechnology Index